Cyclerion Therapeutics, Inc. (CYCN) 10-Year Financial Performance & Capital Metrics

CYCN • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutCyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $2M
EBITDA -$4M +71.8%
Net Income -$3M +41.9%
EPS (Diluted) -1.21 +86.5%
Gross Margin 100%
EBITDA Margin -181.4%
Operating Margin -181.4%
Net Margin -152.85%
ROE -30.36% +37.3%
ROIC -58.3% +97.6%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.4x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Sales declining 15.0% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-15%

3Y-15.54%

TTM1371.65%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM58.36%

EPS CAGR

10Y-

5Y-

3Y-

TTM64.15%

ROCE

10Y Avg-85.51%

5Y Avg-70.91%

3Y Avg-72.78%

Latest-36.03%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	4.51M	2.3M	3.32M	297K	0	2M
Revenue Growth %	-	-	-	-0.49%	0.45%	-0.91%	-1%	-
Cost of Goods Sold+	1.75M	1.53M	95.14M	56.41M	0	5.58M	0	0
COGS % of Revenue	-	-	21.11%	24.57%	-	18.78%	-	-
Gross Profit+	-1.75M	-1.53M	-90.63M	-54.12M	3.32M	-5.28M	0	2M
Gross Margin %	-	-	-20.11%	-23.57%	1%	-17.78%	-	1%
Gross Profit Growth %	-	0.12%	-58.31%	0.4%	1.06%	-2.59%	1%	-
Operating Expenses+	93.92M	115.25M	34.4M	27.15M	58.52M	13.26M	12.95M	5.63M
OpEx % of Revenue	-	-	7.63%	11.82%	17.63%	44.64%	-	2.81%
Selling, General & Admin	15.12M	27.54M	34.4M	28.82M	20.62M	13.26M	8.33M	5.34M
SG&A % of Revenue	-	-	7.63%	12.55%	6.21%	44.64%	-	2.67%
Research & Development	78.8M	87.72M	95.14M	56.41M	37.64M	5.98M	1.51M	286K
R&D % of Revenue	-	-	21.11%	24.57%	11.34%	20.13%	-	0.14%
Other Operating Expenses	0	0	-95.14M	-58.08M	259K	-5.98M	3.1M	0
Operating Income+	-93.92M	-115.25M	-125.04M	-81.27M	-55.2M	-18.54M	-12.95M	-3.63M
Operating Margin %	-	-	-27.74%	-35.39%	-16.63%	-62.42%	-	-1.81%
Operating Income Growth %	-	-0.23%	-0.08%	0.35%	0.32%	0.66%	0.3%	0.72%
EBITDA+	-92.18M	-113.72M	-122.34M	-78.97M	-54.72M	-18.48M	-12.89M	-3.63M
EBITDA Margin %	-	-	-27.14%	-34.39%	-16.48%	-62.21%	-	-1.81%
EBITDA Growth %	-	-0.23%	-0.08%	0.35%	0.31%	0.66%	0.3%	0.72%
D&A (Non-Cash Add-back)	1.75M	1.53M	2.7M	2.3M	472K	65K	65K	0
EBIT	-93.92M	-115.25M	-125.04M	-82.93M	-54.31M	-18.54M	-9.65M	-3.63M
Net Interest Income+	0	0	2.03M	588K	-16K	294K	358K	208K
Interest Income	0	0	2.03M	588K	0	294K	358K	208K
Interest Expense	0	0	0	0	16K	0	0	0
Other Income/Expense	0	0	2.03M	3.46M	3.55M	294K	358K	571K
Pretax Income+	-93.92M	-115.25M	-123.01M	-77.8M	-51.65M	-18.25M	-12.59M	-3.06M
Pretax Margin %	-	-	-27.29%	-33.89%	-15.56%	-61.43%	-	-1.53%
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	2.42%	0.42%	1%
Net Income+	-93.92M	-115.25M	-123.01M	-77.8M	-51.65M	-44.08M	-5.26M	-3.06M
Net Margin %	-	-	-27.29%	-33.89%	-15.56%	-148.41%	-	-1.53%
Net Income Growth %	-	-0.23%	-0.07%	0.37%	0.34%	0.15%	0.88%	0.42%
Net Income (Continuing)	-93.92M	-115.25M	-123.01M	-77.8M	-51.65M	-18.25M	-12.59M	-3.06M
Discontinued Operations	0	0	0	0	0	-25.83M	7.33M	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-68.80	-84.42	-88.37	-47.80	-26.40	-20.15	-8.99	-1.21
EPS Growth %	-	-0.23%	-0.05%	0.46%	0.45%	0.24%	0.55%	0.87%
EPS (Basic)	-68.80	-84.42	-88.37	-47.80	-26.40	-20.15	-8.99	-1.21
Diluted Shares Outstanding	1.37M	1.37M	1.37M	1.52M	1.96M	2.17M	2.34M	2.52M
Basic Shares Outstanding	1.37M	1.37M	1.37M	1.52M	1.96M	2.17M	2.34M	2.52M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.26M	879K	101.2M	58.5M	55.46M	14.82M	8.02M	4.22M
Cash & Short-Term Investments	0	0	97.59M	54.4M	53.96M	13.38M	7.57M	3.23M
Cash Only	0	0	97.59M	54.4M	53.96M	13.38M	7.57M	3.23M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	1.47M	127K	100K	96K	0	556K
Days Sales Outstanding	-	-	119.37	20.19	10.99	117.98	-	101.47
Inventory	0	0	0	0	928K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	8K	12K	162K	1.56M	468K	537K	11K	16K
Total Non-Current Assets+	4.21M	6.52M	85.28M	56.88M	3.87M	3.26M	5.35M	5.35M
Property, Plant & Equipment	4.13M	6.5M	79.75M	50.27M	1.47M	1.22M	0	0
Fixed Asset Turnover	-	-	0.06x	0.05x	2.26x	0.24x	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	4.99M	0	0	0	5.35M	5.35M
Other Non-Current Assets	80K	25K	540K	6.61M	2.41M	2.04M	0	0
Total Assets+	5.47M	7.4M	186.48M	115.38M	59.33M	18.08M	13.37M	9.57M
Asset Turnover	-	-	0.02x	0.02x	0.06x	0.02x	-	0.21x
Asset Growth %	-	0.35%	24.2%	-0.38%	-0.49%	-0.7%	-0.26%	-0.28%
Total Current Liabilities+	14.04M	17.85M	18.25M	16.95M	11.09M	7.63M	2.09M	725K
Accounts Payable	1.8M	2.78M	3.31M	1.15M	1.83M	2.97M	1.2M	390K
Days Payables Outstanding	376.92	664.31	12.7	7.43	-	194.31	-	-
Short-Term Debt	0	0	3.42M	3.51M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	5.62M	7.27M	5.05M	176K	7.28M	68K	102K	63K
Current Ratio	0.09x	0.05x	5.55x	3.45x	5.00x	1.94x	3.85x	5.83x
Quick Ratio	0.09x	0.05x	5.55x	3.45x	4.92x	1.94x	3.85x	5.83x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	70.5M	38.93M	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	70.5M	38.93M	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	14.04M	17.85M	88.75M	55.88M	11.09M	7.63M	2.09M	725K
Total Debt+	0	0	73.92M	45.73M	0	0	0	0
Net Debt	0	0	-23.68M	-8.66M	-53.96M	-13.38M	-7.57M	-3.23M
Debt / Equity	-	-	0.76x	0.77x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-3449.69x	-	-	-
Total Equity+	-8.57M	-10.45M	97.73M	59.49M	48.25M	10.45M	11.29M	8.85M
Equity Growth %	-	-0.22%	10.36%	-0.39%	-0.19%	-0.78%	0.08%	-0.22%
Book Value per Share	-6.28	-7.65	71.39	39.14	24.65	4.81	4.83	3.51
Total Shareholders' Equity	-8.57M	-10.45M	97.73M	59.49M	48.25M	10.45M	11.29M	8.85M
Common Stock	0	0	0	0	0	0	0	0
Retained Earnings	0	0	-85.63M	-163.43M	-215.08M	-259.15M	-264.42M	-267.49M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-15.87M	-15.49M	-20K	-27K	-23K	-20K	-12K	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-81.22M	-97.5M	-102.22M	-72.49M	-36.52M	-40.61M	-21.25M	-4.33M
Operating CF Margin %	-	-	-22.68%	-31.57%	-11%	-136.74%	-	-2.17%
Operating CF Growth %	-	-0.2%	-0.05%	0.29%	0.5%	-0.11%	0.48%	0.8%
Net Income	-93.92M	-115.25M	-123.01M	-77.8M	-51.65M	-18.25M	-12.59M	-3.06M
Depreciation & Amortization	1.75M	1.53M	2.7M	2.3M	472K	65K	0	0
Stock-Based Compensation	9.49M	12.43M	19.63M	14.99M	9.61M	0	0	625K
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	12.59M	14.51M	751K	-4.38M	3.64M	-19.58M	-4.05M	-363K
Working Capital Changes	1.47M	3.79M	-2.29M	-7.59M	1.41M	-2.85M	-4.6M	-1.54M
Change in Receivables	0	0	-1.47M	1.35M	27K	4K	96K	-556K
Change in Inventory	0	0	-3.18M	0	0	0	0	0
Change in Payables	392K	979K	-250K	-1.1M	393K	1.14M	-1.77M	-445K
Cash from Investing+	-1.4M	-3.44M	-6.71M	18K	1.46M	0	10.4M	0
Capital Expenditures	-1.4M	-3.44M	-6.89M	-1.52M	-7K	0	0	0
CapEx % of Revenue	-	-	1.53%	0.66%	0%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	173K	1.54M	1.46M	0	0	0
Cash from Financing+	82.62M	100.94M	211.57M	28.09M	30.79M	29K	5.02M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	82.62M	100.94M	36.57M	331K	282K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-82.62M	-100.94M	-109.1M	-74.01M	-36.52M	-40.61M	-21.25M	-4.33M
FCF Margin %	-	-	-24.21%	-32.24%	-11%	-136.74%	-	-2.17%
FCF Growth %	-	-0.22%	-0.08%	0.32%	0.51%	-0.11%	0.48%	0.8%
FCF per Share	-60.52	-73.94	-79.70	-48.69	-18.66	-18.69	-9.09	-1.72
FCF Conversion (FCF/Net Income)	0.86x	0.85x	0.83x	0.93x	0.71x	0.92x	4.04x	1.42x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-281.86%	-98.97%	-95.87%	-150.19%	-48.42%	-30.36%
Return on Invested Capital (ROIC)	-	-	-294.86%	-97.61%	-183.5%	-	-2468.42%	-58.3%
Gross Margin	-	-	-2010.94%	-2357.06%	100%	-1778.45%	-	100%
Net Margin	-	-	-2729.27%	-3388.59%	-1555.63%	-14841.08%	-	-152.85%
Debt / Equity	-	-	0.76x	0.77x	-	-	-	-
Interest Coverage	-	-	-	-	-3449.69x	-	-	-
FCF Conversion	0.86x	0.85x	0.83x	0.93x	0.71x	0.92x	4.04x	1.42x
Revenue Growth	-	-	-	-49.06%	44.6%	-91.05%	-100%	-

Revenue by Segment

	2024
License Agreement	1.75M
License Agreement Growth	-
License	250K
License Growth	-

Frequently Asked Questions

Growth & Financials

Cyclerion Therapeutics, Inc. (CYCN) reported $2.9M in revenue for fiscal year 2024.

Cyclerion Therapeutics, Inc. (CYCN) grew revenue by 0.0% over the past year. Growth has been modest.

Cyclerion Therapeutics, Inc. (CYCN) reported a net loss of $2.2M for fiscal year 2024.

Dividend & Returns

Cyclerion Therapeutics, Inc. (CYCN) has a return on equity (ROE) of -30.4%. Negative ROE indicates the company is unprofitable.

Cyclerion Therapeutics, Inc. (CYCN) had negative free cash flow of $1.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cyclerion Therapeutics, Inc. (CYCN) 10-Year Financial Performance & Capital Metrics

CYCN • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $2M
EBITDA -$4M +71.8%
Net Income -$3M +41.9%
EPS (Diluted) -1.21 +86.5%
Gross Margin 100%
EBITDA Margin -181.4%
Operating Margin -181.4%
Net Margin -152.85%
ROE -30.36% +37.3%
ROIC -58.3% +97.6%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.4x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Sales declining 15.0% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-15%

3Y-15.54%

TTM1371.65%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM58.36%

EPS CAGR

10Y-

5Y-

3Y-

TTM64.15%

ROCE

10Y Avg-85.51%

5Y Avg-70.91%

3Y Avg-72.78%

Latest-36.03%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	4.51M	2.3M	3.32M	297K	0	2M
Revenue Growth %	-	-	-	-0.49%	0.45%	-0.91%	-1%	-
Cost of Goods Sold+	1.75M	1.53M	95.14M	56.41M	0	5.58M	0	0
COGS % of Revenue	-	-	21.11%	24.57%	-	18.78%	-	-
Gross Profit+	-1.75M	-1.53M	-90.63M	-54.12M	3.32M	-5.28M	0	2M
Gross Margin %	-	-	-20.11%	-23.57%	1%	-17.78%	-	1%
Gross Profit Growth %	-	0.12%	-58.31%	0.4%	1.06%	-2.59%	1%	-
Operating Expenses+	93.92M	115.25M	34.4M	27.15M	58.52M	13.26M	12.95M	5.63M
OpEx % of Revenue	-	-	7.63%	11.82%	17.63%	44.64%	-	2.81%
Selling, General & Admin	15.12M	27.54M	34.4M	28.82M	20.62M	13.26M	8.33M	5.34M
SG&A % of Revenue	-	-	7.63%	12.55%	6.21%	44.64%	-	2.67%
Research & Development	78.8M	87.72M	95.14M	56.41M	37.64M	5.98M	1.51M	286K
R&D % of Revenue	-	-	21.11%	24.57%	11.34%	20.13%	-	0.14%
Other Operating Expenses	0	0	-95.14M	-58.08M	259K	-5.98M	3.1M	0
Operating Income+	-93.92M	-115.25M	-125.04M	-81.27M	-55.2M	-18.54M	-12.95M	-3.63M
Operating Margin %	-	-	-27.74%	-35.39%	-16.63%	-62.42%	-	-1.81%
Operating Income Growth %	-	-0.23%	-0.08%	0.35%	0.32%	0.66%	0.3%	0.72%
EBITDA+	-92.18M	-113.72M	-122.34M	-78.97M	-54.72M	-18.48M	-12.89M	-3.63M
EBITDA Margin %	-	-	-27.14%	-34.39%	-16.48%	-62.21%	-	-1.81%
EBITDA Growth %	-	-0.23%	-0.08%	0.35%	0.31%	0.66%	0.3%	0.72%
D&A (Non-Cash Add-back)	1.75M	1.53M	2.7M	2.3M	472K	65K	65K	0
EBIT	-93.92M	-115.25M	-125.04M	-82.93M	-54.31M	-18.54M	-9.65M	-3.63M
Net Interest Income+	0	0	2.03M	588K	-16K	294K	358K	208K
Interest Income	0	0	2.03M	588K	0	294K	358K	208K
Interest Expense	0	0	0	0	16K	0	0	0
Other Income/Expense	0	0	2.03M	3.46M	3.55M	294K	358K	571K
Pretax Income+	-93.92M	-115.25M	-123.01M	-77.8M	-51.65M	-18.25M	-12.59M	-3.06M
Pretax Margin %	-	-	-27.29%	-33.89%	-15.56%	-61.43%	-	-1.53%
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	2.42%	0.42%	1%
Net Income+	-93.92M	-115.25M	-123.01M	-77.8M	-51.65M	-44.08M	-5.26M	-3.06M
Net Margin %	-	-	-27.29%	-33.89%	-15.56%	-148.41%	-	-1.53%
Net Income Growth %	-	-0.23%	-0.07%	0.37%	0.34%	0.15%	0.88%	0.42%
Net Income (Continuing)	-93.92M	-115.25M	-123.01M	-77.8M	-51.65M	-18.25M	-12.59M	-3.06M
Discontinued Operations	0	0	0	0	0	-25.83M	7.33M	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-68.80	-84.42	-88.37	-47.80	-26.40	-20.15	-8.99	-1.21
EPS Growth %	-	-0.23%	-0.05%	0.46%	0.45%	0.24%	0.55%	0.87%
EPS (Basic)	-68.80	-84.42	-88.37	-47.80	-26.40	-20.15	-8.99	-1.21
Diluted Shares Outstanding	1.37M	1.37M	1.37M	1.52M	1.96M	2.17M	2.34M	2.52M
Basic Shares Outstanding	1.37M	1.37M	1.37M	1.52M	1.96M	2.17M	2.34M	2.52M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.26M	879K	101.2M	58.5M	55.46M	14.82M	8.02M	4.22M
Cash & Short-Term Investments	0	0	97.59M	54.4M	53.96M	13.38M	7.57M	3.23M
Cash Only	0	0	97.59M	54.4M	53.96M	13.38M	7.57M	3.23M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	1.47M	127K	100K	96K	0	556K
Days Sales Outstanding	-	-	119.37	20.19	10.99	117.98	-	101.47
Inventory	0	0	0	0	928K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	8K	12K	162K	1.56M	468K	537K	11K	16K
Total Non-Current Assets+	4.21M	6.52M	85.28M	56.88M	3.87M	3.26M	5.35M	5.35M
Property, Plant & Equipment	4.13M	6.5M	79.75M	50.27M	1.47M	1.22M	0	0
Fixed Asset Turnover	-	-	0.06x	0.05x	2.26x	0.24x	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	4.99M	0	0	0	5.35M	5.35M
Other Non-Current Assets	80K	25K	540K	6.61M	2.41M	2.04M	0	0
Total Assets+	5.47M	7.4M	186.48M	115.38M	59.33M	18.08M	13.37M	9.57M
Asset Turnover	-	-	0.02x	0.02x	0.06x	0.02x	-	0.21x
Asset Growth %	-	0.35%	24.2%	-0.38%	-0.49%	-0.7%	-0.26%	-0.28%
Total Current Liabilities+	14.04M	17.85M	18.25M	16.95M	11.09M	7.63M	2.09M	725K
Accounts Payable	1.8M	2.78M	3.31M	1.15M	1.83M	2.97M	1.2M	390K
Days Payables Outstanding	376.92	664.31	12.7	7.43	-	194.31	-	-
Short-Term Debt	0	0	3.42M	3.51M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	5.62M	7.27M	5.05M	176K	7.28M	68K	102K	63K
Current Ratio	0.09x	0.05x	5.55x	3.45x	5.00x	1.94x	3.85x	5.83x
Quick Ratio	0.09x	0.05x	5.55x	3.45x	4.92x	1.94x	3.85x	5.83x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	70.5M	38.93M	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	70.5M	38.93M	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	14.04M	17.85M	88.75M	55.88M	11.09M	7.63M	2.09M	725K
Total Debt+	0	0	73.92M	45.73M	0	0	0	0
Net Debt	0	0	-23.68M	-8.66M	-53.96M	-13.38M	-7.57M	-3.23M
Debt / Equity	-	-	0.76x	0.77x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-3449.69x	-	-	-
Total Equity+	-8.57M	-10.45M	97.73M	59.49M	48.25M	10.45M	11.29M	8.85M
Equity Growth %	-	-0.22%	10.36%	-0.39%	-0.19%	-0.78%	0.08%	-0.22%
Book Value per Share	-6.28	-7.65	71.39	39.14	24.65	4.81	4.83	3.51
Total Shareholders' Equity	-8.57M	-10.45M	97.73M	59.49M	48.25M	10.45M	11.29M	8.85M
Common Stock	0	0	0	0	0	0	0	0
Retained Earnings	0	0	-85.63M	-163.43M	-215.08M	-259.15M	-264.42M	-267.49M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-15.87M	-15.49M	-20K	-27K	-23K	-20K	-12K	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-81.22M	-97.5M	-102.22M	-72.49M	-36.52M	-40.61M	-21.25M	-4.33M
Operating CF Margin %	-	-	-22.68%	-31.57%	-11%	-136.74%	-	-2.17%
Operating CF Growth %	-	-0.2%	-0.05%	0.29%	0.5%	-0.11%	0.48%	0.8%
Net Income	-93.92M	-115.25M	-123.01M	-77.8M	-51.65M	-18.25M	-12.59M	-3.06M
Depreciation & Amortization	1.75M	1.53M	2.7M	2.3M	472K	65K	0	0
Stock-Based Compensation	9.49M	12.43M	19.63M	14.99M	9.61M	0	0	625K
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	12.59M	14.51M	751K	-4.38M	3.64M	-19.58M	-4.05M	-363K
Working Capital Changes	1.47M	3.79M	-2.29M	-7.59M	1.41M	-2.85M	-4.6M	-1.54M
Change in Receivables	0	0	-1.47M	1.35M	27K	4K	96K	-556K
Change in Inventory	0	0	-3.18M	0	0	0	0	0
Change in Payables	392K	979K	-250K	-1.1M	393K	1.14M	-1.77M	-445K
Cash from Investing+	-1.4M	-3.44M	-6.71M	18K	1.46M	0	10.4M	0
Capital Expenditures	-1.4M	-3.44M	-6.89M	-1.52M	-7K	0	0	0
CapEx % of Revenue	-	-	1.53%	0.66%	0%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	173K	1.54M	1.46M	0	0	0
Cash from Financing+	82.62M	100.94M	211.57M	28.09M	30.79M	29K	5.02M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	82.62M	100.94M	36.57M	331K	282K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-82.62M	-100.94M	-109.1M	-74.01M	-36.52M	-40.61M	-21.25M	-4.33M
FCF Margin %	-	-	-24.21%	-32.24%	-11%	-136.74%	-	-2.17%
FCF Growth %	-	-0.22%	-0.08%	0.32%	0.51%	-0.11%	0.48%	0.8%
FCF per Share	-60.52	-73.94	-79.70	-48.69	-18.66	-18.69	-9.09	-1.72
FCF Conversion (FCF/Net Income)	0.86x	0.85x	0.83x	0.93x	0.71x	0.92x	4.04x	1.42x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-281.86%	-98.97%	-95.87%	-150.19%	-48.42%	-30.36%
Return on Invested Capital (ROIC)	-	-	-294.86%	-97.61%	-183.5%	-	-2468.42%	-58.3%
Gross Margin	-	-	-2010.94%	-2357.06%	100%	-1778.45%	-	100%
Net Margin	-	-	-2729.27%	-3388.59%	-1555.63%	-14841.08%	-	-152.85%
Debt / Equity	-	-	0.76x	0.77x	-	-	-	-
Interest Coverage	-	-	-	-	-3449.69x	-	-	-
FCF Conversion	0.86x	0.85x	0.83x	0.93x	0.71x	0.92x	4.04x	1.42x
Revenue Growth	-	-	-	-49.06%	44.6%	-91.05%	-100%	-

Revenue by Segment

	2024
License Agreement	1.75M
License Agreement Growth	-
License	250K
License Growth	-

Frequently Asked Questions

Growth & Financials

Cyclerion Therapeutics, Inc. (CYCN) reported $2.9M in revenue for fiscal year 2024.

Cyclerion Therapeutics, Inc. (CYCN) grew revenue by 0.0% over the past year. Growth has been modest.

Cyclerion Therapeutics, Inc. (CYCN) reported a net loss of $2.2M for fiscal year 2024.

Dividend & Returns

Cyclerion Therapeutics, Inc. (CYCN) has a return on equity (ROE) of -30.4%. Negative ROE indicates the company is unprofitable.

Cyclerion Therapeutics, Inc. (CYCN) had negative free cash flow of $1.4M in fiscal year 2024, likely due to heavy capital investments.